Dexcom (DXCM) Fundamental Analysis: Revenue, Earnings & Valuation

6.62 / 10

Outperform

Fundamental analysis rates DXCM as Outperform with a 6.62 score. Strong ROE (34.5%), ROA (13%), profit‑margin and cash metrics drive the rating, while the Asset‑MV factor lags. Overall quality is satisfactory, supporting a constructive investment stance.

Analysis Checks(9/10)

ROA (%)

Value13.04

Score3/3

Weight8.87%

1M Return1.79%

Annualized return on equity (%)

Value34.50

Score3/3

Weight8.05%

1M Return1.64%

Profit-MV

Value0.54

Score2/3

Weight15.91%

1M Return3.26%

Cash-UP

Value-0.84

Score3/3

Weight16.47%

1M Return3.34%

Annualized net profit margin on total assets (%)

Value13.04

Score3/3

Weight8.87%

1M Return1.79%

ROE (diluted) (%)

Value30.46

Score3/3

Weight6.75%

1M Return1.39%

Asset-MV

Value-0.55

Score1/3

Weight3.01%

1M Return0.71%

ROE (%)

Value34.50

Score3/3

Weight8.05%

1M Return1.64%

Cash-MV

Value-0.57

Score3/3

Weight13.80%

1M Return2.65%

Net profit / Total profit (%)

Value76.84

Score3/3

Weight10.21%

1M Return2.09%

Is DXCM undervalued or overvalued?

DXCM scores 6.62/10 on fundamentals and holds a Discounted valuation at present. Backed by its 34.50% ROE, 17.94% net margin, 30.41 P/E ratio, 9.26 P/B ratio, and 46.58% earnings growth, these metrics solidify its Outperform investment rating.